The data were published at the annual world congress of the European Society of Medical Oncology (ESMO)

BARCELONA, SPAIN, September 16, 2024 /EINPresswire.com/ -- Kience has presented the results of the first validation study of its innovative non-invasive test based on a blood and urine sample. This test, especially aimed at people aged 40 and over, promises to provide early and accurate screening for up to 42 different types of solid tumors and 5 hematological malignancies (even in the early stages), before the first symptoms and signs appear, precisely when treatment is most likely to be successful.

The test is claimed to be much less invasive, more economical and more guaranteed to offer fewer false positives than other tests currently on the market to detect different types of cancer, thanks to being based on a machine learning algorithm of its own creation that includes, among other innovations, the Barcelona Criteria, four criteria established by Dr. Rafael Molina† together with other members of the Spanish Society of Clinical Chemistry (SEQCML) in 1994, on the correct interpretation of tumor markers.

For the development of the algorithm, Kience initially used a sample size (n) of 192,090 patients, which is the sample resulting from the agglutination of more than 1,600 previous studies (some of them acquired through different technology transfer contracts with the developing medical centers). It was then processed using complex mathematical functions, mainly serial and parallel approximations, to increase specificity and sensitivity, respectively. From here, a sample of 314 patients (166 in the final sample) was recruited to validate the efficacy of the test. The blood and urine samples of these patients were analyzed by Laboratorio Echevarne (Sant Cugat del Vallès, Barcelona), and subsequently processed with the algorithm for the evaluation of their results.

Without the application of the Barcelona Criteria, the algorithm achieved a sensitivity of 100% but a specificity of only 67%, with a positive predictive value (PPV) of 21%. In contrast, when applying the Barcelona Criteria, the specificity was 100% and the PPV improved considerably, also reaching 100%. Even so, it is important to note that these results were obtained with a final sample of 166 patients (148 patients were excluded from the trial because they did not meet any of the trial criteria). Nevertheless, the results themselves demonstrate how important it is to include the Barcelona Criteria in any test that makes use of tumor markers (such as cancer screening tests), in order to avoid false positives and, consequently, overdiagnosis errors.

The company has launched a new international clinical trial with 26,000 patients to further improve the accuracy of the algorithm in the general population. This new trial will run from September 2024 to December 2026.

About Kience Inc.

Kience is a biotechnology company based in Delaware, U.S., resulting from the integration of the Catalan companies Cloud Health Solutions, Bioprognos and Blueberry Diagnostics, focused on the development of revolutionary tests for the prevention, screening and diagnostic confirmation of cancer.

More information: https://www.kience.com

Ángel Plana
Kience Inc.
+34 659 61 51 84
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.